Chimeric Therapeutics Limited
CHMMF
$0.001
-$0.029-96.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -49.38% | -48.20% | -331.67% | -325.96% | 261.20% |
| Total Revenue | -49.38% | -48.20% | -331.67% | -325.96% | 261.20% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -49.38% | -48.20% | -331.67% | -325.96% | 261.20% |
| SG&A Expenses | -16.83% | -14.89% | -39.17% | -40.67% | -35.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.85% | -8.77% | -23.46% | -25.34% | -37.72% |
| Operating Income | -251.40% | -254.95% | -11.12% | -8.38% | 114.95% |
| Income Before Tax | -214.70% | -217.39% | -3.59% | -1.04% | 120.18% |
| Income Tax Expenses | 288.66% | 293.31% | 797.44% | 797.44% | -169.39% |
| Earnings from Continuing Operations | -216.93% | -219.66% | -4.25% | -1.68% | 120.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -216.93% | -219.66% | -4.25% | -1.68% | 120.62% |
| EBIT | -251.40% | -254.95% | -11.12% | -8.38% | 114.95% |
| EBITDA | -196.87% | -199.13% | -10.76% | -8.03% | 119.91% |
| EPS Basic | -164.29% | -171.43% | 45.37% | 46.36% | 115.56% |
| Normalized Basic EPS | -220.00% | -220.00% | 41.79% | 43.48% | 108.93% |
| EPS Diluted | -164.29% | -171.43% | 45.37% | 46.36% | 115.56% |
| Normalized Diluted EPS | -220.00% | -220.00% | 41.79% | 43.48% | 108.93% |
| Average Basic Shares Outstanding | 80.22% | 80.22% | 89.94% | 89.94% | 30.41% |
| Average Diluted Shares Outstanding | 80.22% | 80.22% | 89.94% | 89.94% | 30.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |